284 related articles for article (PubMed ID: 21471647)
21. A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine.
Rüther E; Glaser A; Bleich S; Degner D; Wiltfang J
Pharmacopsychiatry; 2000 May; 33(3):103-8. PubMed ID: 10855461
[TBL] [Abstract][Full Text] [Related]
22. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
Olin JT; Bhatnagar V; Reyes P; Koumaras B; Meng X; Brannan S
Int J Geriatr Psychiatry; 2010 Apr; 25(4):419-26. PubMed ID: 19670390
[TBL] [Abstract][Full Text] [Related]
23. Memantine in everyday clinical practice: a comparison of studies in Germany and Greece.
Förstl H; Stamouli SS; Janetzky W; Galanopoulos A; Karageorgiou C; Tzanakaki M
Dement Geriatr Cogn Disord; 2011; 32(4):267-72. PubMed ID: 22237255
[TBL] [Abstract][Full Text] [Related]
24. Memantine (Ebixa) in clinical practice - results of an observational study.
Calabrese P; Essner U; Forstl H
Dement Geriatr Cogn Disord; 2007; 24(2):111-7. PubMed ID: 17622714
[TBL] [Abstract][Full Text] [Related]
25. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
Grossberg GT; Manes F; Allegri RF; Gutiérrez-Robledo LM; Gloger S; Xie L; Jia XD; Pejović V; Miller ML; Perhach JL; Graham SM
CNS Drugs; 2013 Jun; 27(6):469-78. PubMed ID: 23733403
[TBL] [Abstract][Full Text] [Related]
26. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.
van Dyck CH; Tariot PN; Meyers B; Malca Resnick E;
Alzheimer Dis Assoc Disord; 2007; 21(2):136-43. PubMed ID: 17545739
[TBL] [Abstract][Full Text] [Related]
27. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
Gauthier S; Wirth Y; Möbius HJ
Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444
[TBL] [Abstract][Full Text] [Related]
28. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
29. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease.
Bassil N; Thaipisuttikul P; Grossberg GT
Expert Opin Pharmacother; 2010 Jul; 11(10):1765-71. PubMed ID: 20540654
[TBL] [Abstract][Full Text] [Related]
30. The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia.
Cheon Y; Park J; Joe KH; Kim DJ
Int J Neuropsychopharmacol; 2008 Nov; 11(7):971-83. PubMed ID: 18346293
[TBL] [Abstract][Full Text] [Related]
31. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
32. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
Feldman HH; Schmitt FA; Olin JT;
Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
[TBL] [Abstract][Full Text] [Related]
33. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN
J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
[TBL] [Abstract][Full Text] [Related]
34. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial.
Scheltens P; Kamphuis PJ; Verhey FR; Olde Rikkert MG; Wurtman RJ; Wilkinson D; Twisk JW; Kurz A
Alzheimers Dement; 2010 Jan; 6(1):1-10.e1. PubMed ID: 20129316
[TBL] [Abstract][Full Text] [Related]
36. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
Frölich L; Ashwood T; Nilsson J; Eckerwall G;
J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
[TBL] [Abstract][Full Text] [Related]
37. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.
Schifitto G; Navia BA; Yiannoutsos CT; Marra CM; Chang L; Ernst T; Jarvik JG; Miller EN; Singer EJ; Ellis RJ; Kolson DL; Simpson D; Nath A; Berger J; Shriver SL; Millar LL; Colquhoun D; Lenkinski R; Gonzalez RG; Lipton SA; ; ;
AIDS; 2007 Sep; 21(14):1877-86. PubMed ID: 17721095
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
Bullock R
Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
[TBL] [Abstract][Full Text] [Related]
39. Memantine for dementia.
Areosa SA; Sherriff F
Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
[TBL] [Abstract][Full Text] [Related]
40. A review of the effects of memantine on clinical progression in Alzheimer's disease.
Wilkinson D
Int J Geriatr Psychiatry; 2012 Aug; 27(8):769-76. PubMed ID: 21964871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
